<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855476</url>
  </required_header>
  <id_info>
    <org_study_id>15/0519</org_study_id>
    <nct_id>NCT02855476</nct_id>
  </id_info>
  <brief_title>HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease</brief_title>
  <acronym>HDClarity</acronym>
  <official_title>HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHDI Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HDClarity will seek at least 1200 research participants at different stages of Huntington's
      disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of
      biomarkers and pathways that will enable the development of novel treatments for HD. The
      secondary objective is to generate a high quality plasma sample collection matching the CSF
      collections, which will also be used to evaluate biomarkers and pathways of relevance to HD
      research and development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will attend a screening and sampling visit. During the screening visit,
      medical history, and clinical and phenotypic data will be obtained. Participants who meet the
      eligibility requirements are willing to continue in the study, will return for a sampling
      visit during which ≤20ml CSF and approximately 50ml blood will be collected following an
      overnight fast: blood will be obtained via venipuncture and CSF will be obtained via lumbar
      puncture using local anaesthetic if required. Some participants may be invited to return for
      an Optional Repeat Sampling Visit approximately 4-8 weeks later.

      When participants have completed the Initial Sampling Visit, and Optional Repeat Sampling
      Visit, if relevant, their participation in HDClarity will be considered completed. However,
      participants may be invited to participate in the study multiple times, allowing at least 11
      months between Screening Visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of CSF samples banked</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The primary aim of HDClarity is the generation of a CSF sample repository to facilitate therapeutic development for HD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Huntingtin protein level in cerebrospinal fluid</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The concentration of mutant and total huntingtin level in CSF will be quantified and its relationship to disease severity assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kynurenine metabolites in cerebrospinal fluid</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The concentration of metabolites of the kynurenine pathway in CSF will be quantified and their relationship to disease severity assessed</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>Early Pre-manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Pre-manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD, but who have a higher burden of disease compared to the Early Pre-manifest HD cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage I or Stage II HD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage III HD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage IV-V HD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Have no known family history of HD; or have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CSF, serum, plasma (participant DNA available via Enroll-HD)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A minimum of 1200 male and female participants, aged between 21 and 75 years, inclusive,
        will be enrolled in the study. Eligible participants include healthy controls, people who
        are in the early pre-manifest and late pre-manifest stage of HD, and people diagnosed with
        early HD, moderate HD or advanced HD.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All eligible participants:

             a. Are 21-75 years of age, inclusive; and b. Are capable of providing informed consent
             or have a legal representative authorized to give consent on behalf of the
             participant; and c. Are capable of complying with study procedures, including fasting,
             blood sampling and lumbar puncture; and d. Are participating in the Enroll-HD study;
             and e. Will have had an Enroll-HD visit within two months of the Screening Visit.

          2. For the Healthy Control group, participants eligible are persons who meet the
             following criteria:

             a. Have no known family history of HD; or b. Have known family history of HD but have
             been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD
             (CAG &lt; 36).

          3. For the Early Pre-manifest HD group, participants eligible are persons who meet the
             following criteria:

             a. Do not have clinical diagnostic motor features of HD, defined as Unified
             Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score &lt; 4; and b. Have
             CAG expansion ≥ 40; and c. Have burden of pathology score, computed as (CAG - 35.5) ×
             age, &lt; 250.

          4. For the Late Pre-manifest HD group, participants eligible are persons who meet the
             following criteria:

               1. Do not have clinical diagnostic motor features of HD, defined as Unified
                  Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score &lt; 4; and

               2. Have CAG expansion ≥ 40; and

               3. Have burden of pathology score, computed as (CAG - 35.5) x age, ≥ 250.

          5. For Early Manifest HD group, participants eligible are persons who meet the following
             criteria:

               1. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic
                  Confidence Score = 4; and

               2. Have CAG expansion ≥ 40; and

               3. Have Stage I or Stage II HD, defined as UHDRS Total Functional Capacity (TFC)
                  scores between 7 and 13 inclusive.

          6. For Moderate Manifest HD group, participants eligible are persons who meet the
             following criteria:

               1. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic
                  Confidence Score = 4; and

               2. Have CAG expansion ≥ 40; and

               3. Have Stage III HD, defined as UHDRS TFC scores between 3 and 6, inclusive.

          7. For Advanced Manifest HD group, participants eligible are persons who meet the
             following criteria:

               1. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic
                  Confidence Score = 4; and

               2. Have CAG expansion ≥ 40; and

               3. Have Stage IV HD, defined as UHDRS TFC scores between 0 and 2, inclusive.

        Exclusion Criteria:

        1. For all groups, participants are ineligible if they meet any of the following exclusion
        criteria:

          1. Use of investigational drugs or participation in a clinical drug trial within 30 days
             prior to Sampling Visit; or

          2. Current intoxication, drug or alcohol abuse or dependence; or

          3. If using any medications or nutraceuticals, the use of inappropriate (e.g., non
             prescribed) or unstable dose within 30 days prior to Sampling Visit; or

          4. Significant medical, neurological or psychiatric co-morbidity likely, in the judgment
             of the Site Principal Investigator, to impair participant's ability to complete study
             procedures, or likely to reduce the utility of the samples and data for the study of
             HD; or

          5. Needle phobia, frequent headache, significant lower spinal deformity or major surgery;
             or

          6. Antiplatelet or anticoagulant therapy within the 14 days prior to Sampling Visit,
             including but not limited to: aspirin, clopidogrel, dipyridamole, warfarin,
             dabigatran, rivaroxaban and apixaban; or

          7. Clotting or bruising disorder; or

          8. Screening blood test results more than 10% outside the lab's normal range for the
             following: white cell count, neutrophil count, lymphocyte count, hemoglobin (Hb),
             platelets, prothrombin time (PT) and activated partial thromboplastin time (APTT), or
             any combination of blood test results that the Site Principal Investigator deems to be
             of clinical significance; or

          9. Screening blood test results for C-reactive protein (CRP)&gt;2× upper limit of normal; or

         10. Predictable non-compliance as assessed by Site Principal Investigator; or

         11. Inability or unwillingness to undertake any of the study procedures; or

         12. Exclusion during history or physical examination, final decision to be made by the
             Site Principal Investigator; including but not limited to:

        i. any reason to suspect abnormal bleeding tendency, e.g. easy bruising, petechial rash; or
        ii. any reason to suspect new focal neurological lesion, e.g. new headache, optic disc
        swelling, asymmetric focal long tract signs; or iii. any other reason that, in the clinical
        judgment of the Site Principal Investigator, it is felt that lumbar puncture performed per
        this protocol and associated manuals is unsafe without brain imaging.

        m. Serious Adverse Event (SAE) related to study procedures during or following any previous
        HDClarity Sampling Visit (if applicable), or SAE related to any other lumbar puncture in
        the previous 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward J Wild, MA, MB BChir, MRCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Gosling, BSc</last_name>
    <phone>+44 203 108 7482</phone>
    <email>hdclarity-cc@enroll-hd.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gail Owen, PhD</last_name>
    <phone>+44 1273 640 688</phone>
    <email>g.owen@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ortiz</last_name>
      <phone>303-867-5473</phone>
      <email>kortiz@kumarneuro.com</email>
    </contact>
    <investigator>
      <last_name>Rajeev Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kia Ultz</last_name>
      <phone>410-955-1349</phone>
      <email>kcarte23@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Jee Bang, MPH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine O' Neill</last_name>
      <phone>336-716-8611</phone>
      <email>coneill@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Francis Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Sims</last_name>
      <phone>832-325-7107</phone>
      <email>jamie.sims@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Furr-Stimming</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, The Centre for Huntingtons Disease</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Adurogbangba</last_name>
      <phone>604-822-4872</phone>
      <email>madurogbangba@cmmt.ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Blair Leavitt, MD, CM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Movement Disorders</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Mendoza</last_name>
      <phone>416-847-7084</phone>
      <phone_ext>235</phone_ext>
      <email>smendoza@movementdisorders.ca</email>
    </contact>
    <investigator>
      <last_name>Mark Guttman, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Trautmann</last_name>
      <phone>+49 731 50063023</phone>
      <email>sonja.trautmann@uni-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Jan Lewerenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Josef And Elisabeth Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Kaminski</last_name>
      <email>b.kaminski@klinikum-bochum.de</email>
    </contact>
    <investigator>
      <last_name>Carsten Saft</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Seifert</last_name>
      <phone>+49 9131 85 44751</phone>
      <email>susanne.seifert@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Winkler Jurgen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Huntington Institute</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Kletsch</last_name>
      <phone>+49-251-788-788-0</phone>
      <email>anja.kletsch@ghi-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Reilmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Nanetti</last_name>
      <phone>(+)39 0223942519</phone>
      <email>lorenzo.nanetti@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Mariotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lega Italiana Ricera Huntington</name>
      <address>
        <city>Rome</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara D'Alessio</last_name>
      <phone>(+)39 0644700887</phone>
      <email>barbara.dalessio@lirh.it</email>
    </contact>
    <investigator>
      <last_name>Ferdinando Squitieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Irvine</last_name>
      <phone>01392406979</phone>
      <email>sarah.irvine@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Tim Tim Harrower</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glasgow Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murray Sutherland</last_name>
      <phone>0141 232 7600</phone>
      <email>murray.sutherland@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stuart Ritchie, Mb, ChB, MRCPsych</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Huntingtons Disease Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2 FG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer De Souza</last_name>
      <phone>0121 301 2363</phone>
      <email>jennifer.desouza@bsmhft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Hugh Rickards, MB, ChB, MSc, FRCPsych, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0PY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Andresen</last_name>
      <phone>01223 331141</phone>
      <email>kera2@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Roger Barker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fife Health Board - Whyteman's Brae Hospital</name>
      <address>
        <city>Kirkcaldy</city>
        <zip>KY1 2ND</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fleur Davey</last_name>
      <phone>01383 623623</phone>
      <email>fleurdavey@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Michael Armanyous, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospital Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Callum Schofield</last_name>
      <phone>0113 39 24679</phone>
      <email>callum.schofield@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Emma Hobson, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Walton Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almudena Duran-Rosas, BSc MSc</last_name>
      <phone>0151 525 3611</phone>
      <email>almudena.duran-rosa@thewaltoncentre.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rhys Davies, MA BM BCh PhD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's University Of London</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Goff</last_name>
      <phone>0208 725 5375</phone>
      <email>sally.goff@nihr.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Nayana Lahiri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarsha Wilson</last_name>
      <phone>01865 234607</phone>
      <email>sarsha.wilson@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Richard Armstrong, MA, PhD, BMBCh, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Plymouth NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 5FP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jemma Inches</last_name>
      <phone>01752 432845</phone>
      <email>jinches@NHS.net</email>
    </contact>
    <investigator>
      <last_name>Daniel Lashley, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hdclarity.net</url>
    <description>Study website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College, London</investigator_affiliation>
    <investigator_full_name>Edward Wild</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The cerebrospinal fluid (CSF) and plasma samples collected in this study will be the basis of future biomarker analysis studies. A Scientific Advisory Committee which will decide how the samples will be analysed.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://hdclarity.net/study-information/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://hdclarity.net/study-information/</doc_url>
      <doc_comment>Draft informed consent form, not yet approved by an Institutional Review Board for clinical use</doc_comment>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02855476/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

